Chemours reported a net loss of $29 million in Q1 2026, compared to a $5 million loss in the prior year, mainly due to higher financing and administrative costs. Despite this, the company achieved a 1% increase in net sales to $1.4 billion, driven by record growth in its Thermal & Specialized Solutions segment, especially in Opteon™ and Freon™ refrigerants. Chemours also received $287 million from selling part of its Kuan Yin property, enabling debt repayment and improving liquidity. The company expects Q2 sales to rise 15-20% sequentially and projects full-year sales growth of 3-5%, with ongoing focus on flexible strategies and cost improvements.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
The global waterborne epoxy resins market, valued at $4.98 billion in 2024, is projected to grow at a CAGR of 6.03% to $8.51 billion by 2034. This growth is fueled by strict international regulations targeting volatile organic compound emissions and ...
NEWMEDIA.COM highlights that top ecommerce web design agencies prioritize conversion and scale over just appearance, addressing the nearly 70% cart abandonment rate largely caused by fixable user experience issues like slow pages and complicated chec...
